% Generated from the frozen UroLongevity Version 2.1 bibliography (evidence reviewed through 2026-08-13). Each entry preserves the exact published citation text; structured fields were NOT decomposed, to avoid altering the frozen citations. DOI, PMID, and source URLs are carried verbatim where supplied.

@misc{ULONREF0001,
  title = {{Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011;53:183-189.}},
  author = {{Adunsky}},
  year = {2011},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0001}
}

@misc{ULONREF0002,
  title = {{Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. doi:10.1007/s10522-025-10315-x.}},
  author = {{Al-Dulaimi}},
  year = {2025},
  doi = {10.1007/s10522-025-10315-x},
  url = {https://doi.org/10.1007/s10522-025-10315-x},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0002}
}

@misc{ULONREF0003,
  title = {{Araj M, Brzezik M, Mądra-Gackowska K, Szeleszczuk Ł. Epitalon — 25 years of research. Int J Mol Sci 2025.}},
  author = {{Araj}},
  year = {2025},
  url = {https://www.mdpi.com/1422-0067/26/6/2691},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0003}
}

@misc{ULONREF0004,
  title = {{Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36.}},
  author = {{Aronne}},
  year = {2025},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0004}
}

@misc{ULONREF0005,
  title = {{Badenhorst T, Svirskis D, Wu Z. Pharmaceutical strategies for the topical dermal delivery of peptides/proteins for cosmetic and therapeutic applications. Austin J Pharmacol Ther 2016;4:1083.}},
  author = {{Badenhorst}},
  year = {2016},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0005}
}

@misc{ULONREF0006,
  title = {{Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23:1060-1065. doi:10.1016/j.cmet.2016.05.011.}},
  author = {{Barzilai}},
  year = {2016},
  doi = {10.1016/j.cmet.2016.05.011},
  url = {https://doi.org/10.1016/j.cmet.2016.05.011},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0006}
}

@misc{ULONREF0007,
  title = {{Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14:542-559.}},
  author = {{Bauer}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0007}
}

@misc{ULONREF0008,
  title = {{Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29:1527-1534.}},
  author = {{Beck}},
  year = {2014},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0008}
}

@misc{ULONREF0009,
  title = {{Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol 2019;20:249.}},
  author = {{Bell}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0009}
}

@misc{ULONREF0010,
  title = {{Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife 2022;11:e73420.}},
  author = {{Belsky}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0010}
}

@misc{ULONREF0011,
  title = {{Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest 2020;130:5738-5755.}},
  author = {{Ben-Shlomo}},
  year = {2020},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0011}
}

@misc{ULONREF0012,
  title = {{Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med 2020;26:964-973.}},
  author = {{Berry}},
  year = {2020},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0012}
}

@misc{ULONREF0013,
  title = {{Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010;11:35-46.}},
  author = {{Bjedov}},
  year = {2010},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0013}
}

@misc{ULONREF0014,
  title = {{Bliss M. The Discovery of Insulin. University of Chicago Press; 1982.}},
  author = {{Bliss}},
  year = {1982},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0014}
}

@misc{ULONREF0015,
  title = {{Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432:466-472.}},
  author = {{Bock-Marquette}},
  year = {2004},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0015}
}

@misc{ULONREF0016,
  title = {{Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:364-389.}},
  author = {{Bornstein}},
  year = {2016},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0016}
}

@misc{ULONREF0017,
  title = {{Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab 2022;34:396-407.e6.}},
  author = {{Brakedal}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0017}
}

@misc{ULONREF0018,
  title = {{Brea-Gómez B, Pérez-Llanes R, Ortega-Donaire L, et al. Effectiveness of pelvic floor muscle training with biofeedback in patients undergoing radical prostatectomy: systematic review and meta-analysis. Eur Urol Focus 2025; published online ahead of print.}},
  author = {{Brea-Gómez}},
  year = {2025},
  pmid = {40318944},
  url = {https://pubmed.ncbi.nlm.nih.gov/40318944/},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0018}
}

@misc{ULONREF0019,
  title = {{Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022;387:1547-1556. (NordICC trial.)}},
  author = {{Bretthauer}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0019}
}

@misc{ULONREF0020,
  title = {{Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39:2401-2408. doi:10.1093/eurheartj/ehy217.}},
  author = {{Budoff}},
  year = {2018},
  doi = {10.1093/eurheartj/ehy217},
  url = {https://doi.org/10.1093/eurheartj/ehy217},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0020}
}

@misc{ULONREF0021,
  title = {{Cohen PA, Bass S. Injecting safety into supplements — modernizing the dietary supplement law. N Engl J Med 2019;381:2387-2389.}},
  author = {{Cohen}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0021}
}

@misc{ULONREF0022,
  title = {{Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75:530-535.}},
  author = {{Corpas}},
  year = {1992},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0022}
}

@misc{ULONREF0023,
  title = {{Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31. Correction: Age Ageing. 2019;48:601. doi:10.1093/ageing/afy169.}},
  author = {{Cruz-Jentoft}},
  year = {2019},
  doi = {10.1093/ageing/afy169},
  url = {https://doi.org/10.1093/ageing/afy169},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0023}
}

@misc{ULONREF0024,
  title = {{Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-178.}},
  author = {{Dalmasso}},
  year = {2008},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0024}
}

@misc{ULONREF0025,
  title = {{de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. Treatment Preferences in Patients With Hypothyroidism. J Clin Endocrinol Metab. 2025;110(3):887-900. doi:10.1210/clinem/dgae651.}},
  author = {{de Lima Beltrão}},
  year = {2025},
  doi = {10.1210/clinem/dgae651},
  url = {https://doi.org/10.1210/clinem/dgae651},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0025}
}

@misc{ULONREF0026,
  title = {{Dietary Supplement Health and Education Act of 1994, Pub L No. 103-417, 108 Stat 4325 (codified at 21 USC §§ 321 et seq.).}},
  author = {{United States Congress}},
  year = {1994},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0026}
}

@misc{ULONREF0027,
  title = {{Drug Quality and Security Act, Pub L No. 113-54 (2013).}},
  author = {{United States Congress}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0027}
}

@misc{ULONREF0028,
  title = {{Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452-461. doi:10.1016/S2213-8587(19)30093-2.}},
  author = {{Gong}},
  year = {2019},
  doi = {10.1016/S2213-8587(19)30093-2},
  url = {https://doi.org/10.1016/S2213-8587(19)30093-2},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0028}
}

@misc{ULONREF0029,
  title = {{Eli Lilly and Company. Lilly’s retatrutide reduced body weight by 28.7% in adults living with obesity and knee osteoarthritis in pivotal Phase 3 TRIUMPH-4 study. Press release, December 11, 2025.}},
  author = {{Eli Lilly and Company}},
  year = {2025},
  url = {https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0029}
}

@misc{ULONREF0030,
  title = {{Endocrine Society. Testosterone therapy for hypogonadism guideline resources. Clinical practice guideline, current webpage accessed August 13, 2026.}},
  author = {{Endocrine Society}},
  year = {2026},
  url = {https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0030}
}

@misc{ULONREF0031,
  title = {{Endocrine Society. Statement on testosterone replacement therapy. July 16, 2026.}},
  author = {{Endocrine Society}},
  year = {2026},
  url = {https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0031}
}

@misc{ULONREF0032,
  title = {{Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.}},
  author = {{Eng}},
  year = {1992},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0032}
}

@misc{ULONREF0033,
  title = {{Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34.}},
  author = {{Estruch}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0033}
}

@misc{ULONREF0034,
  title = {{Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-2370.}},
  author = {{Falutz}},
  year = {2007},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0034}
}

@misc{ULONREF0035,
  title = {{Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-4304.}},
  author = {{Falutz}},
  year = {2010},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0035}
}

@misc{ULONREF0036,
  title = {{Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010;53:311-322.}},
  author = {{Falutz}},
  year = {2010},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0036}
}

@misc{ULONREF0037,
  title = {{Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes (Rybelsus). News release, September 20, 2019.}},
  author = {{Food and Drug Administration}},
  year = {2019},
  url = {https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0037}
}

@misc{ULONREF0038,
  title = {{Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act: nomination categories and interim enforcement policy. Current agency webpage, accessed August 13, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2026},
  url = {https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0038}
}

@misc{ULONREF0039,
  title = {{Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Current agency webpage, accessed August 13, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2026},
  url = {https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0039}
}

@misc{ULONREF0040,
  title = {{Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated through May 31, 2026; accessed August 13, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2026},
  url = {https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0040}
}

@misc{ULONREF0041,
  title = {{Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials, including FDA introductory and substance-specific briefing documents for BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500. Accessed August 13, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2026},
  url = {https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0041}
}

@misc{ULONREF0042,
  title = {{Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety communication, February 28, 2025.}},
  author = {{Food and Drug Administration}},
  year = {2025},
  url = {https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0042}
}

@misc{ULONREF0043,
  title = {{Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (Lipfendra). News release, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2026},
  url = {https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0043}
}

@misc{ULONREF0044,
  title = {{Food and Drug Administration. FDA approves treatment for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. News release, 2025; ongoing accelerated-approval confirmatory study status accessed August 13, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2025},
  url = {https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0044}
}

@misc{ULONREF0045,
  title = {{Food and Drug Administration. Drug Trials Snapshot: Forzinity (elamipretide). September 2025; accelerated-approval confirmatory study status accessed August 13, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2025},
  url = {https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0045}
}

@misc{ULONREF0046,
  title = {{Food and Drug Administration. Interim category 2 of the 503A Bulks List. Federal Register, September 29, 2023.}},
  author = {{Food and Drug Administration}},
  year = {2023},
  url = {https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0046}
}

@misc{ULONREF0047,
  title = {{Food and Drug Administration. Removal of certain bulk drug substances from interim category 2 of the 503A Bulks List. Federal Register, April 15, 2026.}},
  author = {{Food and Drug Administration}},
  year = {2026},
  url = {https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0047}
}

@misc{ULONREF0048,
  title = {{Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515.}},
  author = {{Frías}},
  year = {2021},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0048}
}

@misc{ULONREF0049,
  title = {{Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679. doi:10.1016/S0140-6736(06)69701-8.}},
  author = {{Lindström}},
  year = {2006},
  doi = {10.1016/S0140-6736(06)69701-8},
  url = {https://doi.org/10.1016/S0140-6736(06)69701-8},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0049}
}

@misc{ULONREF0050,
  title = {{Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207.}},
  author = {{Gelbard}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0050}
}

@misc{ULONREF0051,
  title = {{Goldstein AL, Low TLK, McAdoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A 1977;74:725-729.}},
  author = {{Goldstein}},
  year = {1977},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0051}
}

@misc{ULONREF0052,
  title = {{Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014;22:613-621.}},
  author = {{Grönberg}},
  year = {2014},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0052}
}

@misc{ULONREF0053,
  title = {{Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. J Dermatolog Treat 2022;33:62-72.}},
  author = {{Gupta}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0053}
}

@misc{ULONREF0054,
  title = {{Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell 2013;49:359-367.}},
  author = {{Hannum}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0054}
}

@misc{ULONREF0055,
  title = {{Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.}},
  author = {{Harman}},
  year = {1956},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0055}
}

@misc{ULONREF0056,
  title = {{Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-395.}},
  author = {{Harrison}},
  year = {2009},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0056}
}

@misc{ULONREF0057,
  title = {{Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 2019;47:446-456.}},
  author = {{Hickson}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0057}
}

@misc{ULONREF0058,
  title = {{HLB Therapeutics. European Phase 3 SEER-3 topline results for RGN-259 in neurotrophic keratopathy. Company notice, June 24, 2025; independent coverage published July 1, 2025.}},
  author = {{HLB Therapeutics}},
  year = {2025},
  url = {https://filecache.investorroom.com/mr5ir_regenerx_ir/215/Letter%20to%20Stockholders%206-24-2025.pdf},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0058}
}

@misc{ULONREF0059,
  title = {{Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. doi:10.20945/2359-4292-2025-0093.}},
  author = {{Hohl}},
  year = {2025},
  doi = {10.20945/2359-4292-2025-0093},
  url = {https://doi.org/10.20945/2359-4292-2025-0093},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0059}
}

@misc{ULONREF0060,
  title = {{Hohl A, Marques P, Ronsoni MF, et al. Selective estrogen receptor modulators (SERMs) for male hypogonadism: a meta-analysis of randomized controlled trials. Arch Endocrinol Metab 2025; published online ahead of print.}},
  author = {{Hohl}},
  year = {2025},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0060}
}

@misc{ULONREF0061,
  title = {{Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet 2018;19:371-384.}},
  author = {{Horvath}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0061}
}

@misc{ULONREF0062,
  title = {{Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013;14:R115.}},
  author = {{Horvath}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0062}
}

@misc{ULONREF0063,
  title = {{Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.}},
  author = {{Hróbjartsson}},
  year = {2012},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0063}
}

@misc{ULONREF0064,
  title = {{Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med 2013;158:781-790.}},
  author = {{Hughes}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0064}
}

@misc{ULONREF0065,
  title = {{Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297. (Cologuard pivotal trial.)}},
  author = {{Imperiale}},
  year = {2014},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0065}
}

@misc{ULONREF0066,
  title = {{Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-4797.}},
  author = {{Ionescu}},
  year = {2006},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0066}
}

@misc{ULONREF0067,
  title = {{Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216.}},
  author = {{Jastreboff}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0067}
}

@misc{ULONREF0068,
  title = {{Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med 2023;389:514-526.}},
  author = {{Jastreboff}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0068}
}

@misc{ULONREF0069,
  title = {{Kaeberlein TL, Green AS, Haddad G, et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience 2023;45:2757-2768.}},
  author = {{Kaeberlein}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0069}
}

@misc{ULONREF0070,
  title = {{Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 2020;117:29959-29967.}},
  author = {{Kawai}},
  year = {2020},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0070}
}

@misc{ULONREF0071,
  title = {{Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592.}},
  author = {{Khavinson}},
  year = {2003},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0071}
}

@misc{ULONREF0072,
  title = {{Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters 2003;24:233-240.}},
  author = {{Khavinson}},
  year = {2003},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0072}
}

@misc{ULONREF0073,
  title = {{Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-1479.}},
  author = {{Khorram}},
  year = {1997},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0073}
}

@misc{ULONREF0074,
  title = {{Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (RECONNECT-1 and RECONNECT-2.)}},
  author = {{Kingsberg}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0074}
}

@misc{ULONREF0075,
  title = {{Klier S, Dananberg J, Masaki L, et al. Safety and efficacy of senolytic UBX1325 in diabetic macular edema. NEJM Evidence 2025;4:EVIDoa2400009.}},
  author = {{Klier}},
  year = {2025},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0075}
}

@misc{ULONREF0076,
  title = {{Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol 1986;15:836-859.}},
  author = {{Kligman}},
  year = {1986},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0076}
}

@misc{ULONREF0077,
  title = {{Kokkinos P, Faselis C, Samuel IBH, et al. Cardiorespiratory fitness and mortality risk across the spectra of age, race, and sex. J Am Coll Cardiol 2022;80:598-609.}},
  author = {{Kokkinos}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0077}
}

@misc{ULONREF0078,
  title = {{Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-1084.}},
  author = {{Kosiborod}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0078}
}

@misc{ULONREF0079,
  title = {{Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454.}},
  author = {{Lee}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0079}
}

@misc{ULONREF0080,
  title = {{Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 2019;25:1843-1850.}},
  author = {{Lehallier}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0080}
}

@misc{ULONREF0081,
  title = {{Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015;386:266-273.}},
  author = {{Leong}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0081}
}

@misc{ULONREF0082,
  title = {{Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 2018;10:573-591. (PhenoAge.)}},
  author = {{Levine}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0082}
}

@misc{ULONREF0083,
  title = {{Lincoff AM, Bhasin S, Flevaris P, et al; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107-117.}},
  author = {{Lincoff}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0083}
}

@misc{ULONREF0084,
  title = {{Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-2232.}},
  author = {{Lincoff}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0084}
}

@misc{ULONREF0085,
  title = {{Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-115.}},
  author = {{Liu}},
  year = {2007},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0085}
}

@misc{ULONREF0086,
  title = {{Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413-446.}},
  author = {{Livingston}},
  year = {2020},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0086}
}

@misc{ULONREF0087,
  title = {{Low TLK, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A 1981;78:1162-1166.}},
  author = {{Low}},
  year = {1981},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0087}
}

@misc{ULONREF0088,
  title = {{Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 2019;11:303-327.}},
  author = {{Lu}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0088}
}

@misc{ULONREF0089,
  title = {{Lucente V, MacDiarmid S, Khera M, et al. Two-year results from a prospective, multicenter, single-arm pivotal study of an implantable tibial neuromodulation system for the treatment of urinary urgency incontinence. Urology 2024;186:80-87.}},
  author = {{Lucente}},
  year = {2024},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0089}
}

@misc{ULONREF0090,
  title = {{Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.}},
  author = {{Lundh}},
  year = {2017},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0090}
}

@misc{ULONREF0091,
  title = {{López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell 2023;186:243-278.}},
  author = {{López-Otín}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0091}
}

@misc{ULONREF0092,
  title = {{López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-1217.}},
  author = {{López-Otín}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0092}
}

@misc{ULONREF0093,
  title = {{Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193-1205.}},
  author = {{Malhotra}},
  year = {2024},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0093}
}

@misc{ULONREF0094,
  title = {{Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 2018;1:e183605.}},
  author = {{Mandsager}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0094}
}

@misc{ULONREF0095,
  title = {{Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014;6:268ra179.}},
  author = {{Mannick}},
  year = {2014},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0095}
}

@misc{ULONREF0096,
  title = {{Mannick JB, Morris M, Hockey HU, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018;10:eaaq1564.}},
  author = {{Mannick}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0096}
}

@misc{ULONREF0097,
  title = {{Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.}},
  author = {{Manson}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0097}
}

@misc{ULONREF0098,
  title = {{Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.}},
  author = {{Marso}},
  year = {2016},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0098}
}

@misc{ULONREF0099,
  title = {{Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.}},
  author = {{Marso}},
  year = {2016},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0099}
}

@misc{ULONREF0100,
  title = {{Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun 2018;9:1286.}},
  author = {{Martens}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0100}
}

@misc{ULONREF0101,
  title = {{McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 2024;15:5046.}},
  author = {{McDermott}},
  year = {2024},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0101}
}

@misc{ULONREF0102,
  title = {{McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-931.}},
  author = {{McEvoy}},
  year = {2016},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0102}
}

@misc{ULONREF0103,
  title = {{Merrifield RB. Solid phase peptide synthesis I: The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-2154. (Nobel Prize in Chemistry, 1984.)}},
  author = {{Merrifield}},
  year = {1963},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0103}
}

@misc{ULONREF0104,
  title = {{MESA Investigators — see Budoff MJ et al. (above) for the contemporary CAC-mortality framework citation.}},
  author = {{MESA Investigators}},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0104}
}

@misc{ULONREF0105,
  title = {{Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025;17:908-936.}},
  author = {{Moel}},
  year = {2025},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0105}
}

@misc{ULONREF0106,
  title = {{Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. eBioMedicine 2017;21:3-4.}},
  author = {{Nadon}},
  year = {2017},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0106}
}

@misc{ULONREF0107,
  title = {{Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647-1659.}},
  author = {{Nair}},
  year = {2006},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0107}
}

@misc{ULONREF0108,
  title = {{Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-611.}},
  author = {{Nass}},
  year = {2008},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0108}
}

@misc{ULONREF0109,
  title = {{Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-2263.}},
  author = {{Ngandu}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0109}
}

@misc{ULONREF0110,
  title = {{Nicholls SJ, Bhatt DL, Buse JB, et al; SURPASS-CVOT Investigators. Cardiovascular efficacy and safety of tirzepatide in patients with type 2 diabetes and atherosclerotic cardiovascular disease. N Engl J Med 2025;393:2347-2358.}},
  author = {{Nicholls}},
  year = {2025},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0110}
}

@misc{ULONREF0111,
  title = {{Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.}},
  author = {{Nishihara}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0111}
}

@misc{ULONREF0112,
  title = {{Nobel Assembly at Karolinska Institutet. The Nobel Prize in Physiology or Medicine 2009: Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak. October 5, 2009.}},
  author = {{Nobel Assembly at Karolinska Institutet}},
  year = {2009},
  url = {https://www.nobelprize.org/prizes/medicine/2009/press-release/},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0112}
}

@misc{ULONREF0113,
  title = {{Novo Nordisk. Evoke and evoke+ trials of oral semaglutide in early Alzheimer’s disease did not meet primary endpoint. Press release, November 24, 2025.}},
  author = {{Novo Nordisk}},
  year = {2025},
  url = {https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0113}
}

@misc{ULONREF0114,
  title = {{Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 2016;167:1719-1733.e12.}},
  author = {{Ocampo}},
  year = {2016},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0114}
}

@misc{ULONREF0115,
  title = {{Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med 2012;367:1969-1972.}},
  author = {{Outterson}},
  year = {2012},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0115}
}

@misc{ULONREF0116,
  title = {{Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093. doi:10.1001/jama.289.16.2083.}},
  author = {{Appel}},
  year = {2003},
  doi = {10.1001/jama.289.16.2083},
  url = {https://doi.org/10.1001/jama.289.16.2083},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0116}
}

@misc{ULONREF0117,
  title = {{Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052.}},
  author = {{Mack}},
  year = {2019},
  doi = {10.1056/NEJMoa1814052},
  url = {https://doi.org/10.1056/NEJMoa1814052},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0117}
}

@misc{ULONREF0118,
  title = {{Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A 1995;92:7001-7005.}},
  author = {{Patchett}},
  year = {1995},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0118}
}

@misc{ULONREF0119,
  title = {{Paulescu NC. Recherche sur le rôle du pancréas dans l’assimilation nutritive. Arch Int Physiol 1921;17:85-103.}},
  author = {{Paulescu}},
  year = {1921},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0119}
}

@misc{ULONREF0120,
  title = {{Penha MÁ, Miot HA, Kasprzak M, et al. Oral minoxidil 5 mg daily versus topical minoxidil 5% twice daily for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol 2024;160:600-605.}},
  author = {{Penha}},
  year = {2024},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0120}
}

@misc{ULONREF0121,
  title = {{Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177:1006-1014.}},
  author = {{Peppard}},
  year = {2013},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0121}
}

@misc{ULONREF0122,
  title = {{Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109-121.}},
  author = {{Perkovic}},
  year = {2024},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0122}
}

@misc{ULONREF0123,
  title = {{Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. JAMA 2005;294:2086-2090.}},
  author = {{Perls}},
  year = {2005},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0123}
}

@misc{ULONREF0124,
  title = {{Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183:1438-1443.}},
  author = {{Peters}},
  year = {2010},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0124}
}

@misc{ULONREF0125,
  title = {{Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.}},
  author = {{Pi-Sunyer}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0125}
}

@misc{ULONREF0126,
  title = {{Pickart L, Thaler MM. Growth-modulating tripeptide (glycyl-histidyl-lysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol 1980;102:129-139.}},
  author = {{Pickart}},
  year = {1980},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0126}
}

@misc{ULONREF0127,
  title = {{Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108.}},
  author = {{Pickart}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0127}
}

@misc{ULONREF0128,
  title = {{Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026.}},
  author = {{Radley}},
  year = {2006},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0128}
}

@misc{ULONREF0129,
  title = {{Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561.}},
  author = {{Raun}},
  year = {1998},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0129}
}

@misc{ULONREF0130,
  title = {{Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med 2021;23:471-478. (TAZPOWER trial.)}},
  author = {{Reid Thompson}},
  year = {2021},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0130}
}

@misc{ULONREF0131,
  title = {{Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12:470.}},
  author = {{Reynolds}},
  year = {2021},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0131}
}

@misc{ULONREF0132,
  title = {{Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4239.}},
  author = {{Romani}},
  year = {2004},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0132}
}

@misc{ULONREF0133,
  title = {{Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179:1066-1071.}},
  author = {{Safarinejad}},
  year = {2008},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0133}
}

@misc{ULONREF0134,
  title = {{Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099.}},
  author = {{Sanyal}},
  year = {2025},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0134}
}

@misc{ULONREF0135,
  title = {{Savin MJ, Wang H, Pei H, et al. Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort. Alzheimers Dement (Amst). 2024;16(4):e70038. doi:10.1002/dad2.70038.}},
  author = {{Savin}},
  year = {2024},
  doi = {10.1002/dad2.70038},
  url = {https://doi.org/10.1002/dad2.70038},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0135}
}

@misc{ULONREF0136,
  title = {{Schmauck-Medina T, Molière A, Lautrup S, et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. Aging (Albany NY) 2022;14:6829-6839.}},
  author = {{Schmauck-Medina}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0136}
}

@misc{ULONREF0137,
  title = {{Schweiger A, Diniz B, Nicol G, et al. Protocol for a pilot clinical trial of the senolytic drug combination dasatinib plus quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025;13:1072. doi:10.12688/f1000research.151963.2.}},
  author = {{Schweiger}},
  year = {2025},
  doi = {10.12688/f1000research.151963.2},
  url = {https://doi.org/10.12688/f1000research.151963.2},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0137}
}

@misc{ULONREF0138,
  title = {{Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993;87:313-327.}},
  author = {{Sikiric}},
  year = {1993},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0138}
}

@misc{ULONREF0139,
  title = {{Simon JA, Kingsberg SA, Goldstein I, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909-917.}},
  author = {{Simon}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0139}
}

@misc{ULONREF0140,
  title = {{Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci 2023;24:554.}},
  author = {{Sosne}},
  year = {2023},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0140}
}

@misc{ULONREF0141,
  title = {{Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821-e830.}},
  author = {{Stanley}},
  year = {2019},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0141}
}

@misc{ULONREF0142,
  title = {{Stealth BioTherapeutics Inc. Stealth BioTherapeutics announces FDA accelerated approval of Forzinity (elamipretide HCl), the first therapy for progressive and life-limiting ultra-rare genetic disease Barth syndrome. Press release, September 19, 2025.}},
  author = {{Stealth BioTherapeutics Inc}},
  year = {2025},
  url = {https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0142}
}

@misc{ULONREF0143,
  title = {{Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 2017;376:2534-2544. (TRUST trial.)}},
  author = {{Stott}},
  year = {2017},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0143}
}

@misc{ULONREF0144,
  title = {{Talpos S. How a Croatian Lab Spawned a Buzzy Peptide Now Popular With MAHA. Undark. February 3, 2026. Co-published by STAT.}},
  author = {{Talpos}},
  year = {2026},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0144}
}

@misc{ULONREF0145,
  title = {{Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799-805.}},
  author = {{Teichman}},
  year = {2006},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0145}
}

@misc{ULONREF0146,
  title = {{The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause 2022;29:767-794.}},
  author = {{North American Menopause Society Advisory Panel}},
  year = {2022},
  url = {https://menopause.org/professional-resources/position-statements},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0146}
}

@misc{ULONREF0147,
  title = {{U.S. Department of Justice. Nicholasville compounding pharmacy and its owner plead guilty to unlawful distribution of prescription drugs. Press release, October 5, 2020. (Tailor Made Compounding LLC.)}},
  author = {{U.S. Department of Justice}},
  year = {2020},
  url = {https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0147}
}

@misc{ULONREF0148,
  title = {{McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619. doi:10.1007/s12178-025-09990-7.}},
  author = {{McGuire}},
  year = {2025},
  doi = {10.1007/s12178-025-09990-7},
  url = {https://doi.org/10.1007/s12178-025-09990-7},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0148}
}

@misc{ULONREF0149,
  title = {{Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012;280:22-35.}},
  author = {{Vandamme}},
  year = {2012},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0149}
}

@misc{ULONREF0150,
  title = {{Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96.}},
  author = {{Vittone}},
  year = {1997},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0150}
}

@misc{ULONREF0151,
  title = {{Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 2022;7:48.}},
  author = {{Wang}},
  year = {2022},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0151}
}

@misc{ULONREF0152,
  title = {{Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392.}},
  author = {{Wharton}},
  year = {2023},
  doi = {10.1056/NEJMoa2302392},
  url = {https://doi.org/10.1056/NEJMoa2302392},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0152}
}

@misc{ULONREF0153,
  title = {{Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.}},
  author = {{Wilding}},
  year = {2021},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0153}
}

@misc{ULONREF0154,
  title = {{Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med 2018;24:1246-1256.}},
  author = {{Xu}},
  year = {2018},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0154}
}

@misc{ULONREF0155,
  title = {{Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-696. doi:10.1056/NEJMoa1100370.}},
  author = {{Zauber}},
  year = {2012},
  doi = {10.1056/NEJMoa1100370},
  url = {https://doi.org/10.1056/NEJMoa1100370},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0155}
}

@misc{ULONREF0156,
  title = {{Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094.}},
  author = {{Zeevi}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0156}
}

@misc{ULONREF0157,
  title = {{Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63.}},
  author = {{Zhang}},
  year = {2009},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0157}
}

@misc{ULONREF0158,
  title = {{Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015;14:644-658.}},
  author = {{Zhu}},
  year = {2015},
  note = {UroLongevity v2.1 frozen bibliography; ref ULON-REF-0158}
}